RT @Yuz6Yusof: #POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in
Tweet Content
#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off